Cargando…

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy

Vision loss in diabetic retinopathy features damage to the blood–retinal barrier and neovascularization, with hypertension and the renin–angiotensin system (RAS) having causal roles. We evaluated if finerenone, a non-steroidal mineralocorticoid receptor (MR) antagonist, reduced vascular pathology an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jerome, Jack R., Deliyanti, Devy, Suphapimol, Varaporn, Kolkhof, Peter, Wilkinson-Berka, Jennifer L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917037/ https://www.ncbi.nlm.nih.gov/pubmed/36768656 http://dx.doi.org/10.3390/ijms24032334

Ejemplares similares

Early Depletion of Neutrophils Reduces Retinal Inflammation and Neovascularization in Mice with Oxygen-Induced Retinopathy
por: Deliyanti, Devy, et al.
Publicado: (2023)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
por: Lima-Posada, Ixchel, et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
por: Dutzmann, Jochen, et al.
Publicado: (2017)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
por: Palanisamy, Srikanth, et al.
Publicado: (2022)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
por: Di Lullo, Luca, et al.
Publicado: (2023)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

SAT-LB106 Metabolic and Brown Adipose Tissue-Specific Effects of the Novel Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in a Mouse Model of Diet-Induced Obesity
por: Marzolla, Vincenzo, et al.
Publicado: (2020)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2020)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina
por: Deliyanti, Devy, et al.
Publicado: (2015)

Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists
por: Marzolla, V., et al.
Publicado: (2021)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
por: Pieronne‐Deperrois, Marie, et al.
Publicado: (2021)

Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628
por: Ma, Frank Y., et al.
Publicado: (2015)

The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis
por: Pei, Hui, et al.
Publicado: (2018)

Abstract 1: Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy
por: Deliyanti, Devy, et al.
Publicado: (2015)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy
por: Yao, Lan, et al.
Publicado: (2023)

Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
por: Kapoor, Kapil G., et al.
Publicado: (2016)

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)

GRK5 is an essential co-repressor of the cardiac mineralocorticoid receptor and is selectively induced by finerenone
por: Pollard, Celina M, et al.
Publicado: (2022)

Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
por: Rahman, Asadur, et al.
Publicado: (2023)

Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
por: Folkerts, Kerstin, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment
por: Kim, Jin Young, et al.
Publicado: (2018)

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
por: Pitt, Bertram, et al.
Publicado: (2013)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Foxp3(+) Tregs are recruited to the retina to repair pathological angiogenesis
por: Deliyanti, Devy, et al.
Publicado: (2017)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9apuj0670j3fgbjj9ad95dl5qe